PARP1 and prostate cancer: Treatment for BRCA-mutated prostate cancer includes PARP inhibitors, which use the phenomenon of synthetic lethality to increase single-strand breaks and DSBs of tumor DNA—which cannot be repaired through a deficient HR or PARP inhibition—and therefore cancer cell death [58].